Page 25 - Read Online

5. Zada G, Bond AE, Wang YP, Giannotta SL, Deapen D. Incidence Cancer Sci 2011;102:2186-90.
trends in the anatomic location of primary malignant brain tumors in 22. Network TC. Corrigendum: Comprehensive genomic characterization
the United States: 1992-2006. World Neurosurg 2012;77:518-24. defines human glioblastoma genes and core pathways. Nature
6. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet 2013;494:506.
A, Scheithauer BW, Kleihues P. The 2007 WHO classification 23. Sabharwal A, Middleton MR. Exploiting the role of O6-
of tumours of the central nervous system. Acta Neuropathol methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
2007;114:97-109. Curr Opin Pharmacol 2006;6:355-63.
7. Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of 24. Kahlert UD, Bender NO, Maciaczyk D, Bogiel T, Bar EE, Eberhart
brain cancer: molecular classification for therapy. Nat Rev Neurosci CG, Nikkhah G, Maciaczyk J. CD133/CD15 defines distinct cell
2004;5:782-92. subpopulations with differential in vitro clonogenic activity and
8. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer stem cell-related gene expression profile in in vitro propagated
Genet 2012;205:613-21. glioblastoma multiforme-derived cell line with a PNET-like
9. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, component. Folia Neuropathol 2012;50:357-68.
Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, 25. Trepant AL, Bouchart C, Rorive S, Sauvage S, Decaestecker C,
O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Demetter P, Salmon I. Identification of OLIG2 as the most specific
Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan glioblastoma stem cell marker starting from comparative analysis
C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson of data from similar DNA chip microarray platforms. Tumour Biol
M, Getz G, Perou CM, Hayes DN. Integrated genomic analysis 2015;36:1943-53.
identifies clinically relevant subtypes of glioblastoma characterized 26. Jeon HM, Kim SH, Jin X, Park JB, Joshi K, Nakano I, Kim H.
by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell Crosstalk between glioma-initiating cells and endothelial cells drives
2010;17:98-110. tumor progression. Cancer Res 2014;74:4482-92.
10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn 27. Ilkanizadeh S, Lau J, Huang M, Foster DJ, Wong R, Frantz A, Wang S,
MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Weiss WA, Persson AI. Glial progenitors as targets for transformation
Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross in glioma. Adv Cancer Res 2014;121:1-65.
JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant 28. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J,
and adjuvant temozolomide for glioblastoma. N Engl J Med Dirks PB. Identification of a cancer stem cell in human brain tumors.
2005;352:987-96. Cancer Res 2003;63:5821-8.
11. Chao ST, Suh JH. When should radiotherapy for low-grade glioma be 29. Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, Chen R, McLendon
given--immediately after surgery or at the time of progression? Nat RE, Friedman AH, Keir ST, Bigner DD, Li QJ, Wang XF. miR-33a
Clin Pract Oncol 2006;3:136-7. promotes glioma-initiating cell self-renewal via PKA and NOTCH
12. Chamberlain MC. Temozolomide: therapeutic limitations in the pathways. J Clin Invest 2014;124:4489-502.
treatment of adult high-grade gliomas. Expert Rev Neurother 30. Chen Y, Wang Z, Dai X, Fei X, Shen Y, Zhang M, Wang A, Li X,
2010;10:1537-44. Huang Q, Dong J. Glioma initiating cells contribute to malignant
13. Taal W, Bromberg JE, van den Bent MJ. Chemotherapy in glioma. transformation of host glial cells during tumor tissue remodeling via
CNS Oncol 2015;4:179-92. PDGF signaling. Cancer Lett 2015;365:174-81.
14. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, 31. Aldaz B, Sagardoy A, Nogueira L, Guruceaga E, Grande L, Huse JT,
Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Aznar MA, Diez-Valle R, Tejada-Solis S, Alonso MM, Fernandez-
Iafrate AJ, Louis DN. Loss of the mismatch repair protein MSH6 Luna JL, Martinez-Climent JA, Malumbres R. Involvement of
in human glioblastomas is associated with tumor progression during miRNAs in the differentiation of human glioblastoma multiforme
temozolomide treatment. Clin Cancer Res 2007;13:2038-45. stem-like cells. PLoS One 2013;8:e77098.
15. Chao TF, Xiong HH, Liu W, Chen Y, Zhang JX. MiR-21 mediates the 32. Sato A, Sunayama J, Matsuda K, Seino S, Suzuki K, Watanabe
radiation resistance of glioblastoma cells by regulating PDCD4 and E, Tachibana K, Tomiyama A, Kayama T, Kitanaka C. MEK-
hMSH2. J Huazhong Univ Sci Technolog Med Sci 2013;33:525-9. ERK signaling dictates DNA-repair gene MGMT expression and
16. Gao J, Wang Z, Liu H, Wang L, Huang G. Liposome encapsulated temozolomide resistance of stem-like glioblastoma cells via the
of temozolomide for the treatment of glioma tumor: preparation, MDM2-p53 axis. Stem Cells 2011;29:1942-51.
characterization and evaluation. Drug Discov Ther 2015;9:205-12. 33. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB,
17. Song S, Mao G, Du J, Zhu X. Novel RGD containing, temozolomide- Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote
loading nanostructured lipid carriers for glioblastoma multiforme radioresistance by preferential activation of the DNA damage
chemotherapy. Drug Deliv 2015; 27:1-5. response. Nature 2006;444:756-60.
18. Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH. 34. Rao SA, Santosh V, Somasundaram K. Genome-wide expression
Encapsulation of temozolomide in a tumor-targeting nanocomplex profiling identifies deregulated miRNAs in malignant astrocytoma.
enhances anti-cancer efficacy and reduces toxicity in a mouse model Mod Pathol 2010;23:1404-17.
of glioblastoma. Cancer Lett 2015;369:250-8. 35. Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S,
19. Grossman R, Burger P, Soudry E, Tyler B, Chaichana KL, Weingart J, Wu A. A five-miRNA signature with prognostic and predictive value
Olivi A, Gallia GL, Sidransky D, Quinones-Hinojosa A, Ye X, Brem for MGMT promoter-methylated glioblastoma patients. Oncotarget
H. MGMT inactivation and clinical response in newly diagnosed GBM 2015;6:29285-95.
patients treated with Gliadel. J Clin Neurosci 2015 22:1938-42. 36. Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E,
20. Natsume A, Kinjo S, Yuki K, Kato T, Ohno M, Motomura K, Iwami Smrcka M, Svoboda M, Dolezalova H, Novakova J, Valik D,
K, Wakabayashi T. Glioma-initiating cells and molecular pathology: Vyzula R, Michalek J. MicroRNA-181 family predicts response to
implications for therapy. Brain Tumor Pathol 2011;28:1-12. concomitant chemoradiotherapy with temozolomide in glioblastoma
21. Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E, patients. Neoplasma 2010;57:264-9.
Svoboda M, Dolezelova H, Smrcka M, Vyzula R, Michalek J, Hajduch 37. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V,
M, Slaby O. MiR-195, miR-196b, miR-181c, miR-21 expression Suzuki K, Hayashi K, Matsuo T, Kamada K, Nagata I, Yamashita
levels and O-6-methylguanine-DNA methyltransferase methylation S. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired
status are associated with clinical outcome in glioblastoma patients. temozolomide resistance in glioblastoma multiforme cells. Cancer

108
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ March 11, 2016 ¦